(NASDAQ GM: CDNA)
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of CareDx, Inc.("CareDx" or the "Company") on behalf of stockholders. A class action complaint has been filed against CareDx. The complaint alleges that defendants engaged in a variety of improper and illegal schemes to inflate testing services revenue, including: (i) pushing protocols for surveillance of organ rejection through inaccurate marketing materials and in violation of Medicare standards; (ii) offering extravagant inducements or kickbacks to physicians and other providers; and (iii) improperly bundling expensive testing services with other blood tests as part of the RemoTraC service. These practices, and others, subjected CareDx to an undisclosed risk of regulatory scrutiny and rendered the Company's testing services revenue and demand reported artificially inflated. As a result, defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.